Candriam S.C.A. purchased a new stake in Celcuity Inc. (NASDAQ:CELC - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 263,590 shares of the company's stock, valued at approximately $3,450,000. Candriam S.C.A. owned about 0.71% of Celcuity at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its holdings in Celcuity by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 237,706 shares of the company's stock valued at $3,112,000 after acquiring an additional 16,035 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Celcuity by 20.3% during the 4th quarter. Bank of New York Mellon Corp now owns 64,125 shares of the company's stock valued at $839,000 after acquiring an additional 10,828 shares during the period. New York State Common Retirement Fund grew its holdings in shares of Celcuity by 14.9% during the 4th quarter. New York State Common Retirement Fund now owns 28,391 shares of the company's stock worth $372,000 after purchasing an additional 3,682 shares in the last quarter. Rhumbline Advisers increased its position in shares of Celcuity by 20.6% in the fourth quarter. Rhumbline Advisers now owns 38,755 shares of the company's stock worth $507,000 after purchasing an additional 6,625 shares during the period. Finally, Bleakley Financial Group LLC bought a new stake in Celcuity during the fourth quarter worth about $146,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.
Celcuity Trading Up 5.2 %
NASDAQ:CELC traded up $0.54 during trading hours on Wednesday, hitting $10.88. 181,053 shares of the company were exchanged, compared to its average volume of 260,105. The company has a fifty day simple moving average of $11.66 and a 200 day simple moving average of $13.45. Celcuity Inc. has a one year low of $8.53 and a one year high of $22.19. The stock has a market capitalization of $403.97 million, a price-to-earnings ratio of -4.17 and a beta of 0.65. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on CELC. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Celcuity in a research report on Friday, November 15th. Needham & Company LLC lifted their price target on Celcuity from $23.00 to $29.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Celcuity presently has a consensus rating of "Buy" and an average price target of $30.17.
Get Our Latest Analysis on Celcuity
Celcuity Company Profile
(
Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Stories
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
